Colcher D, Hand P H, Nuti M, Schlom J
Cancer Invest. 1983;1(2):127-38. doi: 10.3109/07357908309042415.
Splenic lymphocytes of mice immunized with membrane enriched fractions of human mammary carcinomas were fused with the NS-1 nonsecretory++ myeloma cell line. The resulting hybridomas were screened for the synthesis of immunoglobulins reactive with human mammary tumor associated antigens, and two IgG monoclonal antibodies (B1.1 and F5.5) were identified as being reactive with purified carcinoembryonic antigen (CEA). These antibodies were shown to bind to different epitopes on CEA based on their differential reactivities to five different purified CEA preparations, and their differential binding to the surface of tumor cells derived from various organ sites. Monoclonal B1.1 bound equally to the surface of human breast, colon, and melanoma cell lines. Monoclonal F5.5, on the other hand, did not react with the surface of melanoma cell lines, and showed a differential binding to breast carcinoma versus colon carcinoma cells. Monoclonals F5.5 and B1.1 were both used in immunoperoxidase studies with fixed tissue sections of a variety of histologic types of human mammary carcinomas and were shown to be reactive with 55% and 66%, respectively, of tumor masses.
用富集人乳腺癌细胞膜成分免疫的小鼠脾淋巴细胞与NS-1非分泌性骨髓瘤细胞系融合。对产生的杂交瘤进行筛选,以寻找与人乳腺肿瘤相关抗原发生反应的免疫球蛋白,鉴定出两种IgG单克隆抗体(B1.1和F5.5)与纯化的癌胚抗原(CEA)发生反应。基于它们对五种不同纯化CEA制剂的差异反应性以及它们对源自不同器官部位的肿瘤细胞表面的差异结合,这些抗体显示与CEA上的不同表位结合。单克隆抗体B1.1与人乳腺癌、结肠癌和黑色素瘤细胞系的表面具有同等的结合力。另一方面,单克隆抗体F5.5不与黑色素瘤细胞系的表面发生反应,并且对乳腺癌细胞和结肠癌细胞表现出差异结合。单克隆抗体F5.5和B1.1均用于对多种组织学类型的人乳腺癌固定组织切片进行免疫过氧化物酶研究,结果显示它们分别与55%和66%的肿瘤块发生反应。